Tamoxifen and Breast Cancer
Tamoxifen is one of the most widely prescribed drugs used to prevent the recurrence of breast cancer. A nonsteroidal antiestrogen, it has been successful in treating postmenopausal women at nearly all stages of breast cancer. Despite its popularity, disturbing questions remain about the use of this drug. How effective is tamoxifen in treating patients who have hormone-insensitive breast tumors or who have not yet reached menopause? What are the potential risks in taking tamoxifen, and do they ever outweigh its benefits? Should tamoxifen be administered as a prophylactic drug for healthy premenopausal women who are at high risk of developing breast cancer?
In this vitally important book, two leading scientific investigators present a balanced and accessible discussion of the diagnosis of breast cancer and the risks, benefits, and limitations of treatment alternatives, particularly tamoxifen. Michael W. DeGregorio and Valerie J. Wiebe discuss the history and evolution of tamoxifen as a treatment for breast cancer, explaining how it works, what its side effects are, and why tamoxifen treatment is unsuccessful for some women. They present the controversies surrounding the National Cancer Institute's study of tamoxifen as a preventive for breast cancer, describing the hopes of the proponents of the study and the fears of its detractors (potential risks to women in the study include thrombosis, uterine cancer, and even breast cancer itself). The book is an invaluable aid to women faced with decisions about treatment or prevention of breast cancer.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
5-fluorouracil adjuvant adjuvant tamoxifen adriamycin antiestrogenic associated benefit from tamoxifen biopsy breast cancer cells breast cancer patients cell growth chemo clinical trials CMFVP cyclophosphamide cytotoxic developing breast cancer diagnosis doctor doses early breast cancer effects of tamoxifen endometrial cancer estrogen receptor negative estrogen replacement estrogen-receptor-negative estrogen-receptor-positive forms of hormonal healthy women high risk hormonal agents hormone therapy ifen incidence of breast involved liver cancer long-term Low risk lymph nodes menopausal metastatic metastatic breast cancer methotrexate Oncol osteoporosis ovaries oxifen percent placebo postmenopausal patients postmenopausal women potential premenopausal patients premenopausal women prevention of breast proteins raloxifene receptor-negative reduce rence replacement therapy response rate risk factors risk of breast risk of developing risk of recur side effects spread Stage I Stages suggest that tamoxifen surgery surgical systemic chemotherapy taking tamoxifen tamox tamoxifen resistance tamoxifen therapy thiotepa toremifene toxic treatment of breast tumor tumor recurrence uterine cancer vinblastine
Page 109 - Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial [abstract 3].
Page 99 - Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67:327-332.
Page 99 - Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study.